Floatz logo

Aticaprant

Treatment Resistant Depression

Massachusetts General HospitalSmall moleculePhase 2Dormant
CC
40/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
25/ 100
Competitive Position
81/ 100

Competitive context

235 Active assets in the Treatment Resistant Depression cohort.

Asset / SponsorPhaseRating
Risperdal
Johns Hopkins University
Phase 4BBB
Zelapar
Corium Innovations, Inc.
Phase 4BBB
S-Ketamine
Janssen Research & Development, LLC
Phase 4BBB
EDIVOXETINE
Eli Lilly and Company
Phase 3BBB
Opc-34712
Nova Scotia Health Authority
Phase 4BBB

View all 50 →

Same molecule, other indications

Aticaprant is also rated in:

major depressive disorderDormant
CCC
Indicative ·
50 / 100
View asset →
AnhedoniaDormant
CCC
Indicative ·
50 / 100
View asset →
schizophreniaDormant
D
Indicative ·
30 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →